From Jan Manarite:

To all,

Many of you who have advanced prostate cancer may have been watching a drug in development called Abiraterone Acetate. It is not yet FDA approved, but trials look very good, and side effects appear to be very few. Most common side effects are fluid retention (30.5%), and low potassium (17.1%).

While we wait for FDA approval, which is likely – Abiraterone is now available in a couple of clinical trials that have no placebo. One is currently recruiting in the Northeast US. Here are some basic details.

* Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Basic Criteria:

1. testosterone less than 50
2. metastatic
3. failed chemo
4. no more than 2 different types of previous chemo

Sites are being added every week, but these places are currently recruiting:

* Stamford, Connecticut
* Rockville, Maryland
* Morristown, New Jersey
* East Setauket, New York
* Dunkirk, New York

To find addresses of sites, call Centocor Ortho Biotech at (800) 457-6399

Jan Manarite
PCRI Florida Educational Facilitator
(239) 395-0995